Rare diseases
Investigational molecules
Locations
SPY072 is a protein-based substance classified under immune system diseases in the EU Clinical Trials Information System.[1] It is an investigational medicine, which means it has no marketing authorisation and is available only within clinical trials. The product is supplied by Spyre Therapeutics Inc. and appears in the registry only as a test substance, meaning it is the medicine being investigated rather than a comparison treatment.[1]
The registry records do not describe the molecular target or mechanism of action of SPY072. As a protein-based substance, it belongs to a class of medicines made from biological material rather than chemical synthesis. The trial is designed to measure whether SPY072 reduces disease activity in three rheumatologic conditions, but the specific biological pathway it acts on is not stated in the available data.[1]
SPY072 is prepared as a solution for injection and is given by subcutaneous injection, meaning it is injected under the skin.[1] The trial record lists the dose as 00 mg, which indicates that the dose was not reported in the register. The comparison arm receives a placebo matched to SPY072.
One Phase 2 trial is registered for SPY072, with 416 planned participants.[1] The trial is authorised but not yet reporting results. It is a placebo-controlled study, meaning participants are randomly assigned to receive either SPY072 or a placebo. The trial is divided into three substudies, one for each condition, and each substudy has its own main measurement of effect.
In the rheumatoid arthritis substudy, the main outcome is the change in DAS28-CRP from the start of treatment to week 12. DAS28-CRP is a score that combines counts of tender and swollen joints, a blood marker of inflammation (C-reactive protein, CRP) and the patient's own assessment of disease activity. A lower score means less disease activity.
In the axial spondyloarthritis substudy, the main outcome is the change in ASDAS from the start of treatment to week 16. ASDAS is a score used to measure disease activity in axial spondyloarthritis, combining patient-reported symptoms and a blood marker of inflammation.
In the psoriatic arthritis substudy, the main outcome is the proportion of participants who achieve an ACR20 response at week 16. ACR20 means a 20% improvement in a standard set of measures for arthritis, including joint counts and patient and doctor assessments.
No side effect information is available in the registry record or supplementary sources for SPY072. Because the trial is still ongoing and no results have been published, the safety profile of this investigational medicine is not yet described.
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
